The global market for mRNA Platform was estimated at US$152.0 Billion in 2024 and is projected to reach US$129.1 Billion by 2030, growing at a CAGR of -2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The mRNA platform has emerged as a groundbreaking innovation in the field of biotechnology and pharmaceuticals, revolutionizing the way vaccines and therapeutics are developed and deployed. mRNA, or messenger RNA, acts as a blueprint for protein synthesis within cells, and this technology harnesses that mechanism to instruct cells to produce specific proteins that can trigger an immune response or treat diseases. The success of mRNA-based COVID-19 vaccines, developed by companies like Moderna and Pfizer-BioNTech, has showcased the platform's potential for rapid and scalable vaccine production. Unlike traditional vaccines, which often require months or years to develop, mRNA vaccines can be designed and manufactured much more quickly, providing a crucial tool in responding to emerging infectious diseases. Technological advancements have significantly enhanced the capabilities and applications of the mRNA platform. Innovations in lipid nanoparticle (LNP) delivery systems have improved the stability and efficiency of mRNA molecules, allowing for effective delivery into cells. This has broadened the potential applications of mRNA technology beyond vaccines to include treatments for cancer, genetic disorders, and other diseases. The flexibility of the mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine. Additionally, advancements in synthetic biology and bioinformatics have enabled more precise and efficient mRNA sequence design, optimizing the expression and effectiveness of the encoded proteins. The growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges. Key Insights: Market Growth: Understand the significant growth trajectory of the COVID-19 Vaccine segment, which is expected to reach US$102.1 Billion by 2030 with a CAGR of -6.3%. The Cancer Vaccine segment is also set to grow at 86.1% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $64.5 Billion in 2024, and China, forecasted to grow at an impressive 0.1% CAGR to reach $13.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AstraZeneca PLC, Asuragen, Inc., Catalent Pharma Solutions, Altogen Labs, Arcturus Therapeutics, Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Scope: Segments: Indication (COVID-19 Vaccine, Cancer Vaccine, Other Indications) Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World. Key Topics Covered: MARKET OVERVIEW: Influencer Market Insights, Tariff Impact on Global Supply Chain Patterns, mRNA Platform - Global Key Competitors Percentage Market Share in 2025 (E), Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E). mRNA - A CONCEPTUAL UNDERSTANDING: MRNA: A New Approach to Medicine, Long Wait & Scientific Breakthroughs, mRNA Vaccines - An Introduction, With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development, mRNA: Making Cells Act as Vaccine Factory, mRNA Vaccines: Advantages, mRNA Vaccines: Cons, mRNA Vaccine Approvals, A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine, Traditional Vs. mRNA Vaccines: Key Differences, Traditional Vs. mRNA Vaccines: The Development Process, How mRNA Vaccine Works & Earlier Testing Efforts, mRNA Vaccines: Safety Quotient, Other Notable Efforts Centered on mRNA Technology, Overcoming Challenges, As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community. GLOBAL MARKET OVERVIEW: Global mRNA Vaccines Market on a Dynamic Growth Track, mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market, The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market, Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations. RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE: Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization, UK Clinches the First Position in the World to Approve Pfizer's Vaccine, After UK, US Gives Nod to Pfizer's Vaccine, EU Approves Pfizer's Vaccine, BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU, Novartis Inks Agreement with Pfizer-BioNtech to Support COVID-19 Vaccine Production, FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021), Moderna's mRNA Vaccine Bags Approval from US FDA, Moderna Kick-Starts Inoculation in the US, FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021), Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021), Recent Market Activity. COMPETITIVE SCENARIO: BioNTech - A Pioneer in mRNA-based Vaccines and Therapies, List of BioNTech's mRNA Candidates in Clinical Trials for Cancer, Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All, Moderna's mRNA Prophylactic Vaccines, mRNA Cancer Vaccines, mRNA Intratumoral Immuno-Oncology, mRNA Systemic Secreted & Cell Surface Therapeutics, mRNA Systemic Intracellular Therapeutics, mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon, Noteworthy Startups Exploiting mRNA Technology, Providence Therapeutics, pHion Therapeutics, eTheRNA immunotherapies & 20Med Therapeutics. MARKET TRENDS & DRIVERS: Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead, mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum, Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040, Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market, Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050, Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030, Increasing Healthcare Expenditure to Foster Market Growth, Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth, Global Number of Deaths Caused Due to Communicable Diseases (In 000s), Regulatory Landscape for mRNA Vaccines, Regulatory Pathway Dealing with mRNA Vaccines, mRNA Vaccine Patent Scenario, The Best Route of Administration for mRNA Vaccines. mRNA CANCER VACCINES: Introduction, Cancer Vaccines Vs. Immunotherapies, Clinical Trials of mRNA Encoding Immunostimulants, mRNA Vaccines Vs. DNA Vaccines, Clinical Trials of mRNA Encoding TAAs, mRNA Vaccines Vs. Other Vaccines, Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag), mRNA Benefits Profile, mRNA Vaccines for COVID-19 Pave the Way, Challenges, Personalized mRNA Vaccine, Clinical Overview of mRNA Cancer Vaccines, mRNA encoding Immunostimulants, mRNA vaccine encoding tumor-associated antigens, mRNA vaccine encoding Neoantigen, personalized vaccine, mRNA Influenza Vaccines, Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform, Vaccines Built on mRNA, Clinical Trials for mRNA Vaccines, mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts, mRNA: A Next-Generation Vaccination Approach, Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses, COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots, mRNA Vaccines Vs. Other Flu Shots, mRNA Technology, H/N Spike Proteins & Clinical Trials, mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines, Benefits & Limitations of mRNA Vaccines over Traditional Options. FOCUS ON SELECT PLAYERS: Some of the 96 companies featured in this report include AstraZeneca PLC, Asuragen, Inc., Catalent Pharma Solutions, Altogen Labs, Arcturus Therapeutics, Inc., BioNTech AG, CRISPR Therapeutics, Aldevron, AKESOgen, Inc., baseclick GmbH, chimeron bio, Acuitas Therapeutics, Accent Therapeutics, Accanis Biotech F&E GmbH & Co KG, Avectas. For more information about this report visit ResearchAndMarkets.com.

mRNA Platform Strategic Business Analysis Report 2025 | Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth

The global mRNA platform market was valued at $152.0 billion in 2024 and is projected to decline to $129.1 billion by 2030, growing at a CAGR of -2.7%. This report highlights the technology's role in vaccine and therapeutic development, driven by advancements in lipid nanoparticle delivery, synthetic biology, and bioinformatics. Key applications include COVID-19 vaccines, cancer treatments, and other diseases. Market growth is fueled by rising infectious disease incidence, technological improvements, regulatory support, and substantial public and private investments. The U.S. market is valued at $64.5 billion in 2024, with China expected to grow at 0.1% CAGR to reach $13.8 billion by 2030. The cancer vaccine segment is projected to grow at an 86.1% CAGR, while the COVID-19 vaccine segment is expected to reach $102.1 billion by 2030 at a -6.3% CAGR. Major players include BioNTech, Moderna, AstraZeneca, Catalent Pharma Solutions, and several startups such as Providence Therapeutics and pHion Therapeutics. Recent market activity includes Pfizer-BioNTech vaccine approvals, scaling production, and partnerships like Novartis' agreement with Pfizer-BioNTech.